Physician profile
Van Holden
NPI 1245575265
$20,729.40
in general payments reported to CMS, 2019-2025
17 companies · $2,294 in 2025
The $2,294 reported for 2025 was more than what 88% of Critical Care Medicine (Internal Medicine) providers received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,874 · 2020: $4,271 · 2021: $1,000 · 2022: $2,816 · 2023: $5,451 · 2024: $2,023 · 2025: $2,294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,822 · Travel and Lodging: $3,296 · Consulting Fee: $900 · Education: $750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,822.39 |
| Travel and Lodging | $3,295.77 |
| Consulting Fee | $900.00 |
| Education | $750.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $9,288.30 | 2020-2025 | Da Vinci Surgical System |
| Noah Medical Corporation | $3,996.12 | 2023-2025 | Galaxy |
| Pinnacle Biologics, INC | $2,475.27 | 2019 | |
| Pulmonx Corporation | $1,083.71 | 2019-2025 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Ethicon INC. | $970.00 | 2019-2022 | |
| Ambu A/S | $900.00 | 2024 | |
| Covidien Lp | $353.49 | 2019-2020 | |
| Boston Scientific Corporation | $297.05 | 2022-2025 | Accolade Sr |
| Ambu INC. | $279.43 | 2023-2024 | |
| Astrazeneca Pharmaceuticals Lp | $256.48 | 2019-2025 | Fasenra |
| Galvanize Therapeutics, INC | $239.28 | 2024-2025 | Aliya System |
| Erbe USA INC | $160.32 | 2025 | Vio/Cryo/Apc |
| Coaptech, INC. | $148.34 | 2021 | |
| Medtronic, INC. | $115.14 | 2021-2022 | |
| Olympus America INC. | $109.05 | 2024-2025 | Single-Use Flexible Video Bronchoscope |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shionogi INC | $31.66 | 2025 | Fetroja |
| Olympus Corporation of The Americas | $25.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$50,000.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Van Holden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.